Background: Hepatocellular Carcinoma (HCC) is the third most common cause of cancer death worldwide. The burden of HCC has been increasing in Egypt with a doubling in the incidence rate in the past ten years. Subsequently, novel serum markers are needed to improve the diagnostic accuracy of HCC especially with the low sensitivity of a -Fetoprotein (AFP).
Introduction
HCC has become the commonest solid tumor all over the world and the third leading cause of tumor-Correspondence to: Dr. Ali Abd El-Fattah Yousef, The Department of Internal Medicine, Faculty of Medicine, Tanta University related mortality in many countries [1] . The prognosis of HCC patients is generally very poor with a 5-year survival rate of less than 10-15% owing to deficiency of effective and timely diagnostic methods [2] .
AFP is an important marker for diagnosis of HCC. AFP is very useful if it is markedly increased [3] . Furthermore, the specificity of AFP is low because serum levels of AFP are increased in many patients with hepatitis, cirrhosis and gastrointestinal cancers [4] .
Cytoskeleton Linking Membrane Protein-63 (CLIMP-63), also known as p63, CKAP4, and ERGIC-63, is a 63-kDa nonglycosylated, type II transmembrane protein located in the endoplasmic reticulum [5, 6] . CLIMP-63 is strongly related to the tumor growth, proliferation, invasion, and metastasis [7] .
Based on the previous studies of CLIMP-63 in tumors, we aimed to evaluate whether serum CLIMP-63 can be used as a biomarker in the detection of HCC.
Subjects and Methods
This cross-sectional study was carried out on sixty patients were recruited at outpatient clinic and ICU patients, admitted to Internal Medicine Department at Tanta University Hospital from November 2016 to April 2017. The study also included twenty individuals as a control group.
All participants provided informed written consent and the study was approved by Tanta Faculty of Medicine Ethical Committee. Patients with previous treatment for HCC and patients with other malignancies are excluded from the study. The subjects were divided into 3 groups: Group  I included 30 patients with HCC, Group II included  30 patients with cirrhosis and Group III included  20 healthy individuals of matched age and sex as  a control group. They were subjected to complete history taking including age, sex, residence, occupation, history of hepatic encephalopathy and history of previous intervention for HCC (HCC patients). Full clinical examination, with special emphasis on stigmata of chronic liver disease (ascites, jaundice, limb edema, etc.). Laboratory investigations including Complete Blood Count (CBC), viral markers (HCV Ab and HBs Ag), liver function tests (ALT, AST, serum albumin, serum bilirubin, prothrombin time, activity and INR), blood urea and serum creatinine, serum AFP and serum CLIMP-63 by ELISA. Radiological investigations including abdominal ultrasound and triphasic CT abdomen.
All samples were taken under complete aseptic measures. Eight ml of venous blood samples from antecubital vein were withdrawn under complete aseptic technique and were divided into; 2ml was added to a tube containing EDTA for CBC; 1.8ml was added for a tube containing 0.2ml sodium citrate for prothrombin time estimation and the rest of withdrawn sample was put into a plain tube for serum preparation.
The serum was divided into two aliquots; one aliquot used for liver, renal, viral markers and AFP estimation, and the other aliquot was stored at -20ºC under the manufacture instructions for serum CLIMP-63 determination. Serum CLIMP-63 was done by Human CLIMP-63 ELISA kit (Sun Red) (catalogue No. 201-12-7345).
Statistical analysis:
Statistical presentation and analysis of the present study was conducted, using the mean, standard deviation, chi-square test, t-test, f-test, Linear Correlation Coefficient and ROC-curve by SPSS V.20.
Receiver Operating Characteristic (ROC) curves for serum CLIMP-63 and AFP were constructed, to assess their diagnostic accuracy in distinguishing HCC patients from normal control subjects.
Results
The characteristics of the studied groups as regard demographic data (age & sex), tumor markers (AFP & CLIMP-63) and virology are shown in (Table 1) .
There was no statistical significance between the studied groups as regard age and sex p-value 0.501, 0.434 respectively (Table 1 ). Our results also showed that comparison between HCC group and cirrhosis group as regard virology was statistically non-significant (p-value 0.278) ( Table 1) .
Our results also showed that there was significant increase in AFP and CLIMP-63 levels in HCC group as compared with control and cirrhosis groups with p-value 0.043 and 0.001 respectively (Table 1) . Table (2) showed that correlation between AFP and CLIMP-63 with Child Pugh and MELD scores in HCC group was statistically non-significant. Table ( 3) showed the characteristics of HCC group as regard PVT, number of focal lesions and tumor size. It also showed that there was no statistically significant correlation between CLIMP-63 with PVT and number of focal lesions, but there was statistically significant positive correlation between CLIMP-63 and tumor size (p-value=0.017) Fig. (1) . Considering a cut off value of 5ng/ml for AFP: It shows 75% sensitivity and 70% specificity for HCC diagnosis with area under the curve 0.712 (Table 4 ) Fig. (2A) .
Considering a cut off value of 0.5ng/ml for CLIMP-63: It shows 80% sensitivity and 68% ROC Curve specificity for HCC diagnosis with area under the curve 0.782 (Table 4 ) Fig. (2B) .
Table (5) shows that there is significant increase in serum CLIMP-63 in HCC patients with AFP <10ng/ml as compared with control group (p-value =0.001). 
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Discussion
HCC is the sixth most common cancer in the world [8] . Prognosis of HCC is poor since HCC can be mostly diagnosed at an advantaged stage. Over the past few decades, it has drawn attention worldwide to screen for an early diagnosis of HCC [8] .
However, the limitation of AFP from the low sensitivity as the major serum marker for diagnosis of HCC in clinical practice, reliable and novel markers is urgently needed to improve the diagnostic accuracy for HCC [9, 10] . CLIMP-63 is strongly related to the tumor growth, proliferation, invasion, and metastasis [7] . Expression of CLIMP-63 is significantly associated with tumor size, lymph node metastasis, and TNM stage features and is a prognostic marker in patients with intrahepatic cholangiocarcinoma [9] .
In addition, CLIMP-63 can inhibit tumor intrahepatic metastasis and venous invasion, and is a prognostic marker in patients with HCC [10] . Previous studies of CLIMP-63 in tumors made CLIMP-63 an attractive target as a tumor biomarker.
We had the opportunity to evaluate serum CLIMP-63 in the three groups and correlate it with Child-Pugh score and MELD score. We also compared it with AFP level and compared between AFP and CLIMP-63 in the sensitivity and specificity for HCC diagnosis.
In this study, serum CLIMP-63 levels were significantly increased in patients with HCC, as compared to individuals without cancer (healthy and cirrhosis groups).
Shuangxi Li, et al. [8] agreed with this and also demonstrated that serum CLIMP-63 levels were sequentially increased in HCC according to progression of disease based on the theory of heptocarcinogenesis (hepatitis-cirrhosis-carcinoma sequence).
A study done by Shuang-Xi Li, et al. [10] on hepatic tissue taken by liver biopsy from HCC patients and liver hemangioma patients as normal controls showed that large numbers of HCC patients had high expression of CLIMP-63 in tumor tissues as compared with control group.
Our study showed that the sensitivity and specificity of serum CLIMP-63 for the diagnosis of HCC were 80% and 68%, respectively. For AFP, the sensitivity and specificity were 75% and 70%, respectively.
Shuangxi Li, et al. [8] reported that the sensitivity and specificity of serum CLIMP-63 for the diagnosis of HCC were 76.2% and 65.7%, respectively. For AFP, the sensitivity and specificity were 66.7% and 60%, respectively.
Our study showed that there was significant increase in serum CLIMP-63 in HCC patients with AFP cut off value less than 10ng/ml as compared with control group and this data indicated that estimation of serum CLIMP-63 could increase the diagnostic efficacy when AFP is low or negative and could help in the early detection of HCC.
Shuangxi Li, et al. [8] demonstrated that serum CLIMP-63 increased in HCC patient with AFP cut off value less than 20ng/ml. It also showed that the sensitivity and specificity of CLIMP-63 were better in HCC detection when the AFP cut off value less than 20ng/ml.
Our study showed that there was significant positive correlation between serum CLIMP-63 and tumor size. The study done by Shuang-Xi Li, et al. [10] demonstrated that expression of CLIMP-63 in hepatic tissue of HCC patients had significant positive correlation with tumor size.
Our study showed that there was no significant correlation between serum CLIMP-63 with Portal Vein Thrombosis (PVT) and number of focal lesions.
Shuang-Xi Li, et al. [10] reported that there was no significant correlation between expression of CLIMP-63 in hepatic tissue of HCC patients and number of focal lesions, but it shows that there was a positive correlation between expression of CLIMP-63 and PVT.
The study done by Shuang-Xi Li, et al. [10] also reported that there was a significant positive correlation between expression of CLIMP-63 in hepatic tissue of HCC patients with TNM and BCLC staging systems.
The study done by Shuang-Xi Li, et al. [10] also showed that there was no significant correlation between expression of CLIMP-63 in hepatic tissue of HCC patients and distant metastasis and it also reported that there was no significant correlation between expression of CLIMP-63 in hepatic tissue of HCC patients and presence or absence of cirrhosis.
In this study, there was relatively small sample size and there were small available researches about CLIMP-63 especially its relation to HCC.
Conclusion:
CLIMP-63 may be a novel serum marker for diagnosis of HCC in the early stage and testing serum CLIMP-63 and AFP may improve the detection rate of HCC.
Recommendations:
Serum CLIMP-63 may be used with AFP for early detection of HCC and further studies with larger sample size from different stage of HCC may be needed to confirm and validate CLIMP-63 as a diagnostic marker.
